Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp coverage decision draws Congressional interest

Executive Summary

Centers for Medicare & Medicaid Services asked to provide more information about the basis of its decision to reimburse Amgen's Aranesp (darbepoetin) at the same level as Johnson & Johnson's Procrit (epoetin) under the Outpatient Prospective Payment System final rule, in a Nov. 1 letter from Congressional members. Group requests further details about an "independent contractor" review that deemed the two products "functionally equivalent." The letter is signed by Sens. Grassley (R-Iowa), Baucus (D-Mont.), Hatch (R-Utah), Breaux (D-La.) and Kennedy (D-Mass.), and Reps. Tauzin (R-La.) and Bilirakis (R-Fla.). Amgen responded to the OPPS final rule, issued Oct. 31, by declaring it would work "to correct the inaccuracies in the rule in all appropriate forums" (1"The Pink Sheet" Nov. 4, p. 27)...

You may also be interested in...



Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule

The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

UsernamePublicRestriction

Register

PS040751

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel